• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    President, Surgical Bonnefoy Luc covered exercise/tax liability with 968 shares, decreasing direct ownership by 1% to 73,383 units (SEC Form 4)

    6/16/25 4:46:45 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care
    Get the next $BLCO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Bonnefoy Luc

    (Last) (First) (Middle)
    C/O BAUSCH + LOMB CORPORATION
    520 APPLEWOOD CRESCENT

    (Street)
    VAUGHAN A6 L4K 4B4

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Bausch & Lomb Corp [ BLCO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    President, Surgical
    3. Date of Earliest Transaction (Month/Day/Year)
    06/13/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Shares, No Par Value 06/13/2025 F 968(1) D $12.33 73,383 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units.
    /s/ Debra E. Levin, attorney-in-fact 06/16/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BLCO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLCO

    DatePrice TargetRatingAnalyst
    5/2/2025$20.00 → $15.00Buy
    H.C. Wainwright
    3/28/2025$24.00 → $15.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$24.00 → $22.00Buy → Neutral
    Citigroup
    12/2/2024$19.00Overweight → Equal-Weight
    Morgan Stanley
    10/15/2024$19.00 → $25.00In-line → Outperform
    Evercore ISI
    7/10/2024$19.00Outperform
    Raymond James
    5/6/2024$16.00 → $18.00Equal-Weight → Overweight
    Morgan Stanley
    1/4/2024$19.00 → $17.00Outperform → In-line
    Evercore ISI
    More analyst ratings

    $BLCO
    SEC Filings

    See more
    • Bausch + Lomb Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Bausch & Lomb Corp (0001860742) (Filer)

      6/18/25 4:52:57 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Bausch & Lomb Corp (0001860742) (Filer)

      6/10/25 9:05:43 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • SEC Form SD filed by Bausch + Lomb Corporation

      SD - Bausch & Lomb Corp (0001860742) (Filer)

      5/30/25 4:14:06 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, Surgical Bonnefoy Luc covered exercise/tax liability with 968 shares, decreasing direct ownership by 1% to 73,383 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      6/16/25 4:46:45 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Director Von Eschenbach Andrew C. was granted 20,338 shares, increasing direct ownership by 49% to 62,086 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/28/25 4:11:49 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Director Ross Thomas W. Sr. was granted 20,338 shares, increasing direct ownership by 51% to 60,391 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/28/25 4:10:50 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering

      Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "company"), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the "Issuers"), have priced the offering of €675 million aggregate principal amount of senior secured floating rate notes due 2031 ("Notes"). The size of the offering was increased from the previously announced €600 million aggregate principal amount of Notes. The Notes will be sold to investors at a price of 99.500% of the principal amount thereof. As previously announced, the company is also seeking to partia

      6/18/25 4:30:00 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement

      Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "company"), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the "Issuers"), have launched an offering of €600 million aggregate principal amount of senior secured floating rate notes ("Notes"). In connection with the Notes offering, the company has also launched a partial refinancing of its credit agreement, whereby the company intends to obtain a $2.2 billion new term B loan facility (the "New Term B Loan Facility") and a new $800 million revolving credit facility (the

      6/10/25 8:48:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Launches Blink® Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States

      Blink Nourish and Blink Boost are now available at most U.S. national retailers, including Walmart, Target, CVS, Walgreens and Amazon Blink Nourish is the first and only vitamin-enriched preservative-free eye drop designed to replenish and rebalance the tear film Blink Boost's formula is pH-balanced to match healthy tears, making it comfortable when applied Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink Nourish Lubricating eye drops and Blink Boost Lubricating eye drops. Both products are preservative-free, contact-lens friendly and uniquely formulated to

      6/4/25 6:59:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and Chairman of the Board Saunders Brent L bought $248,072 worth of shares (22,000 units at $11.28) and was granted 22,000 shares, increasing direct ownership by 6% to 741,156 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/27/25 8:16:24 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Director Von Eschenbach Andrew C. bought $19,925 worth of shares (1,695 units at $11.76), increasing direct ownership by 4% to 41,748 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/6/25 4:30:10 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • CEO and Chairman of the Board Saunders Brent L bought $505,067 worth of shares (32,250 units at $15.66) and was granted 32,250 shares, increasing direct ownership by 11% to 627,419 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      8/7/24 5:29:48 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care